

Table of Contents

I.	<u>Introduction</u>	
	Statement of purpose	I-1
	References	I-1
	Link to CDC TB references	I-2
	Link to on-line NC TB Control Manual	I-2
	Contact Information for NC TB Control Medical Director	I-2
	Contact information for expert Pediatric TB consultation	I-3
	TB Nurse Consultant contact information	I-4
	Abbreviations	I-4
II.	<u>Mantoux Tuberculin Skin Testing (TST) and Interferon Gamma Release Assays (IGRAs)</u>	
	TST/IGRA limitations	II-1
	Preferred testing table	II-1
	TST training	II-2
	A. TST Administration	II-2
	B. Reading a TST	II-3
	C. Interpretation of a TST	II-3
	D. False negative TST reactions	II-5
	E. False Positive TST reactions	II-5
	F. TST Converters	II-5
	G. Two-step TST (booster phenomenon)	II-6
	H. BCG (Bacille Calmette-Guerin)	II-6
	I. Candidates for TST/IGRA and people state supplied PPD can be used for	II-6
	1. People legally required to get a TST/IGRA	II-7
	2. People that should be tested when initially presenting for care	II-7
	3. People on immunosuppressive drugs	II-8
	4. Contacts to Children ≤ 2 with a new positive TST/IGRA	II-8
	5. Contacts to a pregnant woman with a new positive TST/IGRA	II-8
	6. Homeless shelter state and clients	II-8
	7. Staff at local jails and detox units	II-8
	8. Staff and residents in settings where TST/IGRA is required	II-9
	J. Chest X-rays	II-9
	K. Two-step TST algorithm	II-10
	L. IGRA guidance	II-11
	M. Quality Control checklist for administering TST's	II-15
	N. Sample standing order for TST placement	II-17
	O. Sample standing order for obtaining IGRA's	II-20
III.	<u>Treatment of Latent TB Infection</u>	
	A. Overview	III-1
	B. Priorities for LTBI treatment	III-1
	1. People at highest priority for LTBI treatment	III-1
	2. People at medium priority for LTBI treatment	III-1

3.	People at low priority for LTBI treatment	III-1
4.	Resource to determine patient’s risk of progression to active TB	III-2
5.	Positive TST and IGRA’s and determining risk	III-2
C.	Standards for managing latent TB infection	III-3
D.	Regimens for Adults ≥ 12 years	
1.	Isoniazid and rifapentine for 12 weeks	III-5
2.	Rifampin for four months	III-5
3.	Isoniazid plus rifampin daily for three months	III-5
4.	Isoniazid for 6-9 months	III-6
5.	Isoniazid and rifapentine for one month	III-6
E.	Regimens for infants and children < 12 years	III-6
1.	Isoniazid and rifapentine for 12 weeks	III-6
2.	Four months of rifampin	III-6
3.	Isoniazid and rifampin for 3 months	III-7
4.	Isoniazid for 6-9 months	III-7
F.	Regimen for Pregnant women	III-7
1.	Chest X-rays	III-7
2.	High risk pregnant women	III-8
3.	Low risk pregnant women	III-8
4.	Treatment regimens	
a.	Rifampin for four months	III-8
b.	Isoniazid for six months	III-8
G.	Pyridoxine	III-9
H.	Drug doses chart for treating LTBI	III-10
I.	Monitoring of LTBI Treatment	III-11
1.	Isoniazid monitoring	III-11
2.	Rifampin monitoring	III-12
3.	Isoniazid and Rifapentine monitoring	III-14
4.	Reporting adverse reactions to the CDC	III-14
J.	Hepatotoxicity flowchart	III-16
K.	Standing order for LTBI	III-19
1.	Sample standing order for Rifapentine and Isoniazid	III-20
2.	Sample standing order for Rifampin	III-23
3.	Sample standing order for Isoniazid	III-28

IV. [Diagnosis and Treatment of TB Disease](#)

A.	Diagnosis and medical evaluation	IV-1
1.	Medical and social history	IV-1
2.	TST and IGRA testing	IV-1
3.	Chest X-ray	IV-1
4.	Bacteriology	IV-1
B.	Airborne precautions and/or home isolation	IV-2
C.	Diagnostics for suspected TB in children	IV-3
D.	Treatment	IV-3

1.	Standards of TB Disease Management	IV-6
2.	Regimen for Adults \geq 12 years with pulmonary TB	IV-6
3.	Regimen for pregnant women	IV-7
4.	Regimen for infants and children less than 12	IV-8
5.	Regimen for HIV negative non-pregnant adults that are Sputum smear and culture negative pulmonary TB	IV-9
6.	Regimen for adults with extra-pulmonary TB	IV-9
7.	Discontinuation of the INH and rifapentine option	IV-10
8.	Treatment of <i>M. bovis</i> including BCG strain	IV-10
E.	Drug resistant TB	IV-11
F.	Pyridoxine when treating active TB	IV-13
G.	Dosing for adults with reduced renal function	IV-13
H.	Directly observed therapy	IV-14
I.	Video Directly observed therapy sample policy	IV-15
J.	Monitoring during treatment of active TB	IV-17
1.	Baseline evaluation	IV-18
2.	Follow-up monitoring	IV-19
3.	Monitoring chart	IV-21
K.	TB Drug Adverse Reactions	IV-22
1.	Common adverse reactions	IV-22
2.	Rash	IV-22
3.	Nausea and vomiting & other GI distress	IV-23
4.	Hepatotoxicity	IV-23
L.	Reintroduction of TB Medications for Hepatotoxicity	IV-23
M.	Flow chart for re-introducing TB medications	IV-24
N.	Hepatotoxicity flowchart	IV-25
O.	Reporting TB cases	IV-27
P.	Death Certificates	IV-30
Q.	Sample TB treatment agreement	IV-31
R.	Sample TB treatment agreement in Spanish	IV-32
S.	TB drug dosages chart	IV-33
T.	Clinical Pathway for managing tuberculosis suspects/cases	IV-34
U.	Tool for reporting suspected or confirmed TB cases	IV-37
V.	Sample standing order for suspected/confirmed TB cases	IV-38
V.	<u>TB and HIV/AIDS</u>	V-1
A.	Standards of treatment and management	V-1
B.	LTBI Screening in People living with HIV	V-2
C.	Candidates for treatment of LTBI	V-2
D.	Chest X-rays prior to treatment of LTBI	V-2
E.	LTBI treatment regimens for people with HIV/AIDS	V-3
1.	Isoniazid and Rifampin for 12 weeks	V-3
2.	Rifampin daily for 4 months	V-3
3.	Isoniazid daily for 9 months	V-3

	4.	Rifabutin daily for 4 months	V-3
	5.	Treatment of LTBI in pregnant women with HIV/AIDS	V-3
F.		Tuberculosis Disease in people with HIV	V-4
	1.	Drugs used to treat TB in people with HIV/AIDS ≥ 13	V-4
	2.	Antiretrovirals and TB drugs	V-5
	3.	Switching from rifampin to rifabutin before starting Anti-retrovirals	V-5
	4.	Serum drug levels	V-5
	5.	Taking TB drugs daily versus intermittently	V-5
	6.	Duration of treatment	V-5
	7.	Regimens for pregnant women	V-5
G.		Antiretroviral Therapy	V-5
VI.		<u>Patient non-adherence</u>	
	A.	Closure of patient record for non-adherence of treatment of LTBI	VI-1
	B.	Patient non-adherence when treating for active TB disease	VI-1
	1.	Evaluate for barriers	VI-1
	2.	Evaluate for non-adherence during the treatment phase	VI-1
	3.	Defining non-adherence	VI-1
	4.	Isolation orders	VI-1
		a. Definition of isolation	VI-1
		b. What an isolation order can do	VI-1
	5.	Compliance order	VI-1
	6.	Intent of isolation and compliance orders	VI-1
	C.	NC Public Health Laws and TB in regard to compliance and isolation	VI-2
	D.	Sample Compliance Order for TB Control	VI-4
	E.	Sample Compliance Order for TB Control in Spanish	VI-6
	F.	Sample Isolation Order to Limit Freedom of Movement	VI-8
	G.	Sample Isolation Order to Limit Freedom of Movement in Spanish	VI-10
	H.	Incarceration procedure	VI-12
	I.	Arrest procedure	VI-12
	J.	Department of Public Safety (DPS) Medical Management	VI-13
	K.	DPS health law violator (HLV) release procedure	VI-13
	L.	NC TB Control (HLV) release letter procedure	VI-13
	M.	Local health department HLV release from prison procedure	VI-14
VII.		<u>TB Drugs</u>	
	A.	NC TB Program TB drug rules	VII-1
	B.	Local health department pharmacy responsibilities	VII-1
	C.	Information about purified protein derivative (PPD)	VII-1
	D.	Ordering TB drugs and record keeping	VII-2
	E.	Common drug interaction resources	VII-3
	F.	TB drug abbreviations	VII-4

VIII.	<u>Contact Investigation</u>	
	A. Link to CDC contact investigation guidelines	VIII-1
	B. Goals of a contact investigation	VIII-1
	C. Prioritization of contacts	VIII-1
	D. Case characteristics	VIII-1
	E. Contact risk factors	VIII-1
	F. Exposure time limits	VIII-2
	G. Structuring a contact investigation	VIII-2
	Table 2 Estimating infectious period	VIII-3
	Figure 1. Table on structuring a contact investigation	VIII-4
	H. Evaluating the contact	VIII-5
	I. Contacts to extra-pulmonary TB	VIII-7
	J. Infant born to a household of someone with active pulmonary TB	VIII-8
	K. Infant with Hematogenous spread of TB disease	VIII-8
	L. Contacts to INH resistant TB disease	VIII-9
	M. Contacts to INH and RIF Resistant TB disease (MDR or XDR)	VIII-9
	N. Contact investigations in a correctional facility	VIII-9
	O. Contact investigation by other health care facilities	VIII-9
	P. Documentation of contact investigations	VIII-9
IX.	<u>American Lung Association (ALA)</u>	
	A. ALA incentive funds	IX-1
	B. ALA emergency housing funds	IX-2
	C. ALA emergency utility funds	IX-3
	D. Incentive fund application	IX-4
	E. Emergency housing form A application	IX-5
	F. Emergency housing form B application	IX-6
	G. Emergency utility application	IX-7
	H. W-9 form	IX-8
X.	<u>Selected Resources</u>	
	A. Charges for services	X-1
	B. Education and resources	X-2
	C. New TB Nurse orientation checklist	X-5
	D. Management of TB suspects/cases in correctional/detention facilities	X-7
	E. Hurricane/Disaster Action Plan	X-11
	F. Cohort review	X-13
	G. Referrals to other states, territories and countries	X-18
XI.	<u>Infection Control</u>	
	A. OSHA and CDC guidance	XI-1
	B. Elements of a TB infection control plan	XI-1
	C. Sample health department tuberculosis control policy	XI-2
	D. TB risk assessment - Appendix D from the CDC guidelines	X-6

E.	TB screening and risk assessment form for newly hired health care personnel	X-13
XII.	<u>Laboratory Services</u>	
A.	State Public Health Lab/mycobacteriology	
	1. Submitting specimens	XI-1
	2. Laboratory results	XI-1
	3. Susceptibility testing	XI-1
	4. Notification to the health department	XI-2
	5. Retention of specimens	XI-2
	6. Universal genotyping program	XI-2
	7. Private laboratory mycobacteriology	XI-2
	8. Nucleic Acid Amplification (NAA) testing	XI-2
	9. Sputum Collection procedure	XI-5
	10. Sputum induction protocol	XI-5
	11. Gastric Aspiration procedure	XI-7
	12. Serum concentration levels for TB drugs	XI-8
	13. NC State Lab mycobacteriology requisition form link	XI-8
	14. Report of positive AFB smear and or culture form link	XI-8
XIII.	<u>Class A and B Notification of Arrival of Immigrants and Refugees</u>	
A.	Classifications	XIII-1
B.	Class A's	XIII-2
C.	Assignment of classification	XIII-3
D.	Creating Class A/B events in NCEDSS	XIII-3
E.	Process for initial evaluation of class A/B	XIII-3
F.	Acknowledging the event in NCEDSS	XIII-3
G.	Documenting the initial evaluation in NCEDSS	XIII-3
H.	Chest X-rays	XIII-3
I.	Completing the class A/B TB worksheet wizard in NCEDSS	XIII-3
J.	Unable to locate class A/B	XIII-4
K.	Documenting treatment	XIII-4
L.	Notifying the TB Nurse Consultant- class A/B TB worksheet is complete	XIII-4
M.	Closing the class A/B event in NCEDSS	XIII-4
N.	Education and assistance	XIII-4
O.	Class A/B's not found in NCEDSS	XIII-4
P.	Link to information about the overseas examination	XIII-4
XIV.	<u>TB Related Laws</u>	
A.	<u>General Statutes</u>	
	1) 15A-534.5 Detention to Protect Public Health-Pre-trial release	XIV-1
	2) 90-21.4 Responsibility, Liability and Immunity of Physicians that report	XIV-1
	3) 90-21.5 Minor's Consent for Certain Medical Health Services	XIV-1

4) 90-85.34A Public Health Pharmacy Practice	XVI-2
5) 115C-323 Employee Health Certificate (Public School Employee)	XVI-3
6) 130A-25 Misdemeanor (Health Law Violator)	XVI-3
7) 130A-134 Reportable Diseases and Conditions	XVI-4
8) 130A-135 Physicians to Report	XVI-4
9) 130A-136 School Principals and Child Care Operators to Report	XVI-4
10) 130A-137 Medical Facilities May Report	XVI-4
11) 130A-139 Persons in Charge of Laboratories to Report	XVI-5
12) 130A-140 Local Health Directors to Report	XVI-5
13) 130A-141 Form, Content and Timing of Reports	XVI-5
14) 130A-141.I Temporary Order to Report	XVI-5
15) 130A-142 Immunity of Persons Who Report (when necessary to protect public)	XVI-6
16) 130A-143 Confidentiality of Records	XVI-6
17) 130A-144 Investigation and Control Measures	XVI-7
a. Health Director to investigate reportable diseases	
b. Records may be released without consent	
c. Immunity for releasing such records without consent	
d. Control measures must be given	
e. Local health department must ensure that control measures are followed and that examination and treatment is given at no cost to the patient	
f. All persons must comply with control measures	
18) 130A-145 Quarantine and Isolation Authority	XVI-8
19) 130A-146 Transportation of Bodies with communicable disease	XVI-9
20) 130A-147 Rules of the Commission for detection, control and prevention	XVI-9
21) 130A-440 Health assessment for initial school entry	XVI-09
22) 153A-225 Medical Care of Prisoners	XVI-11

B. North Carolina Administrative Code

Day Care Rules - Health and Other Standards for Center Staff

1) <u>10A NCAC 09.0701 Health Standards for Child Care Providers</u>	XIV-12
--	--------

Foster Care Rules - Standards for Licensing

2) <u>10A NCAC 70E.1104 Criteria for the Family</u>	XIV-13
---	--------

Rules for Licensing of Group Homes for the Developmentally Disabled

3) <u>10A NCAC 27G.0202 Personnel Requirements</u>	XIV-14
--	--------

Rules for the Licensing of Nursing Homes - General Standards of Administration

4) <u>10A NCAC 13D.2209 Infection Control</u>	XIV-15
---	--------

Rules for Adult Assisted Living Homes, Rest Homes Section .0400 Staff Qualifications

5) 10A NCAC 13F.0406 Test for Tuberculosis XIV-17

Section .0700 - Admission and Discharge

6) 10A NCAC 13F.0703 Tuberculosis Test XIV-17

Licensing of Family Care Homes Staff Qualifications

7) 10A NCAC 13G.0405 Test for Tuberculosis XIV-18

8) 10A NCAC 13G.0907 Respite Care XIV-18

Home Care Rules

9) 10A NCAC 13J.1003 Licensing of Home Care Agencies – Personnel XIV-19

Hospice Rules

10) 10A NCAC 13K.0401 Hospice Licensing Rules – Personnel XIV-21

Jail Rules (Jails, Local Confinement Facilities)

Section .1000 - Health Care of Inmates and Exercise

11) 10A NCAC 14J.1001 Medical Plan XIV-22

12) 10A NCAC 14J.1002 Health Screening Form XIV-22

13) 10A NCAC 14J.1003 Medical Isolation XIV-23

Communicable Disease Rules

Epidemiology Health - Chapter 41, Subchapter 41A - Communicable Disease Control

14) 10A NCAC 41A.0101 Reportable Diseases and Conditions Link XIV-23

15) 10A NCAC 41A.0102 Method Reporting XIV-23

16) 10A NCAC 41A.0103 Duties of Local Health Director: Reporting XIV-25

17) 10A NCAC 41A.0104 Release of Communicable Disease Records for research XIV-26

18) 10A NCAC 41A.0201 Control Measures – General XIV-26

19) 10A NCAC 41A .0202 Control Measures-HIV XIV-28

20) 10A NCAC 41A.0205 Control Measures – Tuberculosis XIV-31

21) 10A NCAC 41A.0206 Infection Control - Health Care Settings XIV-33

22) 10A NCAC 41A.0209 Laboratory Testing- Genotyping XIV-35

23) 10A NCAC 41A.0210 Duties of Attending Physicians XIV-35

24) 10A NCAC 41A.0211 Duties of Other Persons XIV-35

25) 10A NCAC 41A.0907 Release of Information XIV-36

Subchapter 42B - Laboratory Sections

26) <u>10A NCAC 42B.0105 Microbiology – State Lab to Test for Tuberculosis</u>	XIV-36
--	--------

Public Health Services Standards for Local Health Departments

27) <u>10A NCAC 46.0201 Mandated Services</u>	XIV-37
---	--------

28) <u>10A NCAC 46.0214 Communicable Disease Control</u>	XIV-37
--	--------

Pharmacy Rules

29) <u>21 NCAC 46.2401 Medication in Health Departments</u>	XIV-39
---	--------

30) <u>21 NCAC 46.2402 Training of Health Department Nurses</u>	XIV-39
---	--------

31) <u>21 NCAC 46.2403 Drugs and Devices to be Dispensed</u>	XIV-40
--	--------

C. Quick Reference for Tuberculin Skin Testing Requirements

1. <u>Legally Required Tuberculin Skin Testing (TST)</u>	XIV-41
--	--------

2. <u>TST May Be Required by OSHA or Agency Policy</u>	XIV-41
--	--------

3. <u>Other Settings</u>	XIV-42
--------------------------	--------

XV. Record Management

A. Local policy and standing orders	XV-1
-------------------------------------	------

B. Clinical Records and links to TB forms	XV-1
---	------

C. Obtaining records from other providers	XV-2
---	------

D. Transferring records	XV-3
-------------------------	------

E. Record retention	XV-3
---------------------	------